deltatrials

Eli Lilly and Company Clinical Trials

Sponsors / Eli Lilly and Company

Eli Lilly and Company appears as lead sponsor on 2,264 trial records in ClinicalTrials.gov. The portfolio currently includes 148 recruiting studies, 128 active non-recruiting studies, and 1760 completed studies. 169 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include efficacy or futility findings, slow or insufficient recruitment. Cumulative planned enrollment across all listed trials is 1,089,129 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.

2,264
Total Trials
148
Recruiting
128
Other Active
1,760
Completed
169
Terminated / Withdrawn
1,089,129
Total Enrollment

Termination reasons: Other31% · Efficacy29% · Recruitment15% · Safety12% · Business9% · Funding2% · Regulatory1%

Recent Terminations

  • NCT07085468 Phase PHASE2 Stopped Aug 2025
    Healthy
    "Study terminated for strategic business reasons"
  • NCT07030868 Phase PHASE2 Stopped Jul 2025
    Obesity
    "Study terminated for strategic business reasons"
  • NCT05911841 Phase PHASE2 Stopped Mar 2025
    Atopic Dermatitis
    "The decision to terminate the study was due to efficacy/effectiveness reasons."
  • NCT06007651 Phase PHASE1 Stopped Feb 2025
    Dyslipidemias
    "Participants were not dosed in Part B as per the protocol, the patient population will be refined and new outcome measures will be applied in a separate study."
  • NCT05592275 Phase PHASE2 Stopped Jan 2025
    Heart Failure
    "An interim was conducted and after review of available data, including efficacy evaluation of heart failure events, Lilly is terminating the study due to low likelihood of study success for this HFpEF patient population."
  • NCT05516758 Phase PHASE2 Stopped Jan 2025
    Arthritis
    "Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis."
  • NCT07020351 Phase PHASE2 Stopped Dec 2024
    Atopic Dermatitis
    "The study was terminated for lack of efficacy."
  • NCT06119529 Phase PHASE1 Stopped Apr 2024
    Atopic Dermatitis
    "Based on emerging nonclinical data, the study was terminated."
  • NCT05609825 Phase PHASE1 Stopped Jan 2024
    Hypertriglyceridemia
    "The study was terminated due to a change in risk/benefit ratio, which no longer favoured continued development."
  • NCT05794243 Phase PHASE1 Stopped Jun 2023
    Healthy
    "Following preplanned review of the safety and pharmacokinetic data from Part A, it was determined that sufficient data had been obtained. The decision was made to not proceed with Part B and the study was terminated early."

Active Trials (128 total)

See all 128 active trials

Top Conditions

Top Locations